Hereditary neuropathies

Current Opinion in Neurology

Volumn 20, Issue 5, 2007, Pages 542-547

  Parman, Yesim ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Ascorbic acid; Axon; Charcot Marie Tooth; Neurotrophin 3; Progesterone antagonist; Schwann cell

Indexed keywords

ASCORBIC ACID; NEUROTROPHIN 3; ONAPRISTONE;

CELL INTERACTION; CRANIAL NERVE; DISEASE MODEL; ELECTROPHYSIOLOGY; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; HEREDITARY MOTOR SENSORY NEUROPATHY; HISTOPATHOLOGY; HUMAN; NERVE FIBER; NEUROPATHY; NONHUMAN; PATHOGENESIS; PERIPHERAL NERVE; PHENOTYPE; PHYSIOTHERAPY; REVIEW; SCHWANN CELL;

ANIMALS; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; ELECTRODIAGNOSIS; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HEREDITARY MOTOR AND SENSORY NEUROPATHIES; HUMANS; MUTATION; PERIPHERAL NERVES;

EID: 34648844163     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32826fbcb7     Document Type: Review

References (48)

1. Dyck PJ, Lambert EH. Lower motor and primary sensory neuron disease with peroneal muscular atrophy. I: Neurologic, genetic electrophysiologic findings in various neuronal degenerations. Arch Neurol (Chic) 1968; 18:603-618.
2. Dyck PJ, Lambert EH. Lower motor and primary sensory neuron disease with peroneal muscular atrophy. II: Neurologic, genetic electrophysiologic findings in various neuronal degenerations. Arch Neurol (Chic) 1968; 18:619-625.
3. Bird TD, Giblett ER. Evidence for linkage of Charcot-Marie-Tooth neuropathy to the Duffy locus on chromosome 1. Am J Hum Genet 1982; 34:388-394.
4. Niemann A, Berger P, Suter U. Pathomechanisms of mutant proteins in Charcot-Marie-Tooth disease. Neuromolecular Med 2006; 8:217-242. Excellent review summarizing the putative functions and malfunctions of proteins encoded by genes mutated in CMT.
5. Berger P, Niemann A, Suter U. Schwann cells and the pathogenesis of inherited motor and sensory neuropathies (Charcot-Marie-Tooth disease). Glia 2006; 54:243-257. Excellent review focusing on the molecular and cellular mechanisms that cause the Schwann cell pathologies observed in dysmyelinating and demyelinating forms of CMT.
6. Suter U, Scherer SS. Disease mechanisms in inherited neuropathies. Nature 2003; 4:714-726.
7. Villanova M, Timmerman V, DeJonghe P. Charcot-Marie-Tooth disease: an intermediate form. Neuromusc Disord 1998; 8:392-393.
8. Verhoeven K, Villanova M, Rossi A, et al. Localization of the gene for the intermediate form of Charcot-Marie-Tooth to chromosome 10q24.1-q25.1. Am J Hum Genet 2001; 69:889-894.
9. Jordanova A, Thomas FP, Guergueltcheva V, et al. Dominant intermediate Charcot-Marie-Tooth type C maps to chromosome 1p34-35. Am J Hum Genet 2003; 73:1423-1430.
10. Zuchner S, Noureddine M, Kennerson M, et al. Mutations in the pleckstrin homology domain of dynamin 2 cause dominant intermediate Charcot-Marie-Tooth disease. Nat Genet 2005; 37:289-294.
11. Szigeti K, Garcia C, Lupski JR. Charcot-Marie-Tooth disease and related peripheral neuropathies: molecular diagnostics determine aspects of medical management. Genetics Med 2006; 8:86-92.
12. Martin JJ, Brice A, Van broeckhoven C. Workshop of the European CMT-Consortium-62nd ENMC International Workshop: rare forms of Charcot-Marie-Tooth disease and related disorders, 16-18 October 1998, Soestduinen, The Netherlands. Neuromusc Disord 1999; 9:279-287.
13. Pareyson D, Scaioli V, Laura M. Clinical and electrophysiological aspects of Charcot-Marie-Tooth disease. Neuromolecular Med 2006; 8:3-22. A guide for the clinician about the clinical and electrophysiological aspects of CMT.
14. Zuchner S, De Jonghe P, Jordanova A, et al. Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2. Ann Neurol 2006; 59:276-281.
15. Timmerman V, DeJonghe P, Ceuterick C, et al. Novel missense mutation in the early growth response 2 gene associated with Dejerine-Sottas syndrome phenotype. Neurology 1999; 52:1827-1832.
16. Kalaydjieva L, Nikolova A, Turnev I, et al. Hereditary motor and sensory neuropathy-Lom, a novel demyelinating neuropathy associated with deafness in gypsies: clinical, electrophysiological and nerve biopsy findings. Brain 1998; 121:399-408.
17. Colomer J, Gooding R, Angelicheva D, et al. Clinical spectrum of CMT4C disease in patients homozygous for the p.Arg1109X mutation in SH3TC2. Neuromuscul Disord 2006; 16:449-453.
18. Sambuughin N, de Bantel A, McWilliams S, et al. Deafness and CMT disease associated with a novel four aminoacid deletion in the PMP22 gene. Neurology 2003; 60:506-508.
19. Seman P, Mazanec R, Huehne K, et al. Hearing loss as the first feature of late-onset CMT disease due to a novel P0 mutation. Neurology 2004; 63:733-735.
20. Stojkovic T, Latour P, Vandenberghe A, et al. Sensorineural deafness in X-linked Charcot-Marie-Tooth disease with connexin32 mutation. Neurology 1999; 52:1010-1014.
21. Klein CJ, Cunningham JM, Atkinson EJ, et al. The gene for HMSN2C maps to 12q23-24: a region of neuromuscular disorders. Neurology 2003; 60:1151-1156.
22. Sevilla T, Cuesta A, Chumillas MJ, et al. Clinical, electrophysiological and morphological findings of Charcot-Marie-Tooth neuropathy with mutations in GDAP1 gene. Brain 2003; 126:2023-2033.
23. Puls I, Oh SJ, Sumner CJ, et al. Distal spinal and bulbar muscular atrophy caused by dynactin mutation. Ann Neurol 2005; 52:429-434.
24. Takashima H, Boerkoel CF, De Jonghe P, et al. Periaxin mutations cause a broad spectrum of demyelinating neuropathies. Ann Neurol 2002; 51:709-715.
25. Parman Y, Battaloglu E, Baris I, et al. Clinicopathological and genetic study of early-onset demyelinating neuropathy. Brain 2004; 127:2540-2550.
26. De Jonghe P, Timmermann V, Ceuterick C, et al. The Thr124Met mutation in the peripheral protein zero (MPZ) gene is associated with a clinically distinct Charcot-Marie-Tooth phenotype. Brain 1999; 122:281-290.
27. Houlden H, King RHM, Muddle JR, et al. A novel RAB7 mutation associated with ulcero-mutilating neuropathy. Ann Neurol 2004; 56:586-590.
28. Antonellis A, Ellsworth RE, Sambuughin N, et al. Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. Am J Hum Genet 2003; 72:1293-1299.
29. Parman Y, Ciftci F, Poyraz M, et al. X-linked Charcot-Marie-Tooth disease and multiple sclerosis. J Neurol 2007; 30 April [Epub ahead of print].
30. Amato AA, Barohn RJ. Hereditary neuropathy with liability to pressure palsies: association with central nervous system demyelination. Muscle Nerve 1996; 6:770-773.
31. Echaniz-Laguna A, Degos B, Bonnet C, et al. NDRG1-linked Charcot-Marie-Tooth disease (CMT4D) with central nervous system involvement. Neuromuscul Disord 2007; 17:163-168.
32. Chung KW, Kim SB, Park KD, et al. Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutations. Brain 2006; 129:2103-2118.
33. Zhu D, Kennerson ML, Walizada G, et al. Charcot-Marie-Tooth with pyramidal signs is genetically heterogeneous: families with and without MFN2 mutations. Neurology 2005; 65:496-497.
34. Auer-Grumbach M, Schlotter-Weigel B, Lochmullaer H, et al. Phenotypes of the N88S Berardinelli-Seip congenital lipodystrophy 2 mutation. Ann Neurol 2005; 57:415-424.
35. Chen YZ, Bennet CL, Huynh HM, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet 2004; 74:1128-1135.
36. Senderek J, Bergmann C, Stendel C, et al. Mutations in a gene encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy. Am J Hum Genet 2003; 73:1106-1119.
37. Azzedine H, Ravise N, Verny C, Gabreels-Festen A, et al. Spine deformities in Charcot-Marie-Tooth 4C caused by SH3TC2 gene mutations. Neurology 2006; 67:602-606.
38. Azzedine H, Bolino A, Taieb T, et al. Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma. Am J Hum Genet 2003; 72:1141-1153.
39. Hirano R, Takashima H, Umehara F, et al. SET binding factor 2 (SBF2) mutation causes CMT4B with juvenile onset glaucoma. Neurology 2004; 63:577-580.
40. Dubourg O, Tardieu S, Birouk N, et al. Clinical, electrophysiological and molecular genetic characteristics of 93 patients with X-linked Charcot-Marie-Tooth disease. Brain 2001; 124:1958-1967.
41. De Angelis MV, Di Muzio A, Capasso M, et al. Segmental conduction abnormalities and myelin thickenings in Val102/fs null mutation of MPZ gene. Neurology 2004; 63:2180-2183.
42. Meyer zu Horste G, Suter U, Uzma N, Nave KA. Animal models of inherited neuropathies. Curr Opin Neurol 2006; 19:464-473. Paper focusing on animal models that have opened up new perspectives on the pathomechanisms and possible treatment strategies of inherited neuropathies.
43. Sereda MW. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 2003; 9:1533-1537.
44. Meyer zu Horste G, Prukop T, Liebetanz D, et al. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann Neurol 2007; 61:61-72. Using a transgenic rat model of CMT1A, clinical and histopathological results are obtained from long-term treatment with antiprogesterone.
45. Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004; 10:396-401.
46. Kaya F, Belin S, Bourgeois P, et al. Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. Neuromuscul Disord 2007; 17:248-253. Study on the properties of ascorbic acid.
47. Reilly MM, de Jonghe P, Pareyson D. 136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A), 8-10 April 2005, Naarden, The Netherlands. Neuromuscul Disord 2006; 16:396-402. Workshop for the first multicentered trial of ascorbic acid in CMT1A.
48. Sahenk Z, Nagaraja HN, McCracken BS, et al. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology 2005; 65:681-689.